2nd Quarter - Report

BIOGEN for BIOGEN

Firm
Client
Income
—
Expenses
$980,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Discussions regarding Medicaid 340B drug discount program Reducing Out-of-Pocket Costs for Biosimilars in Medicare Part B

LobbyistCovered position, as disclosed
AMY DEMSKE —
CHRISTINA HOCHUL —
MICHELLE MATHY —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE

Trade (domestic/foreign) TRD

IP/Trade TRIPS Waiver

LobbyistCovered position, as disclosed
JONATHAN CAUSEY —
MICHELLE MATHY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS)

Health Issues HCR

Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Appropriations on Alzheimers screening and diagnosis Discussions regarding H.R. 1319, the American Rescue Plan S.1427/H.R.2869, Increasing Access to Biosimilars Act of 2021 H.R.2815, Bolstering Innovative Options to Save Immediately on Medisines (BIOSIM) Act H.R.2855, Star Rating for Biosimilars

LobbyistCovered position, as disclosed
JONATHAN CAUSEY —
AMY DEMSKE —
STEPHANIE A. DYSON —
JOHN RAYMOND GIBSON —
SUSAN KORNETSKY New —
MICHELLE MATHY —
CHUCK SHIH —
CAROLINE TUCKER —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: H.R. 2855 (117th), S. 1427 (117th), H.R. 1319 (117th), H.R. 2869 (117th), H.R. 2815 (117th)

Pharmacy PHA

H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Oppose drug pricing proposals that include international procing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19. S.3129) Education and discussions regarding pharmaceutical issues related to supply chain

LobbyistCovered position, as disclosed
JONATHAN CAUSEY —
STEPHANIE A. DYSON —
MICHELLE MATHY —

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 19 (117th), S. 3129 (117th), H.R. 3 (117th), S. 2543 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.